1. Home
  2. DMAC vs MSC Comparison

DMAC vs MSC Comparison

Compare DMAC & MSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$7.05

Market Cap

342.7M

Sector

Health Care

ML Signal

N/A

Logo Studio City International Holdings Limited

MSC

Studio City International Holdings Limited

N/A

Current Price

$1.81

Market Cap

352.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
DMAC
MSC
Founded
2000
2000
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
342.7M
352.4M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
DMAC
MSC
Price
$7.05
$1.81
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$15.50
N/A
AVG Volume (30 Days)
250.8K
4.7K
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.01
$1.73
52 Week High
$10.42
$6.63

Technical Indicators

Market Signals
Indicator
DMAC
MSC
Relative Strength Index (RSI) 50.25 39.33
Support Level $5.51 N/A
Resistance Level $7.06 $3.35
Average True Range (ATR) 0.53 0.09
MACD -0.07 0.01
Stochastic Oscillator 24.15 29.63

Price Performance

Historical Comparison
DMAC
MSC

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About MSC Studio City International Holdings Limited

Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.

Share on Social Networks: